RxDoctor Payments Data

Charles Sparrow, MD

Family Medicine · Richmond, VANPI 1255339305

Payments from drug & device makers

$8,704in general payments, 2019–2025

Across 507 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • Pfizer$820
  • AstraZeneca$673
  • Lilly USA, LLC$404
  • Amgen$389
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$8,53698%
  • Education$1542%
  • Entertainment$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,704 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$198,242
Medicare patients
388
Services billed
4,358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide51$64,825
EliquisApixaban86$62,842
OzempicSemaglutide34$37,543
XareltoRivaroxaban44$36,593
JanuviaSitagliptin Phosphate37$32,660
JardianceEmpagliflozin26$26,162
FarxigaDapagliflozin Propanediol24$25,076
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$21,245
RybelsusSemaglutide15$18,183
LinzessLinaclotide24$12,764
Metformin Hcl135$8,026
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$7,610
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$7,012
Fentanyl24$4,876
Atorvastatin Calcium523$4,650

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$404$64,82551 claims
PfizerEliquis$820$62,84286 claims
Novo NordiskOzempic, Rybelsus$1,363$55,72549 claims
Johnson & JohnsonXarelto$335$36,59344 claims
MerckJanuvia$212$32,66037 claims
GSKTrelegy Ellipta, Anoro Ellipta$313$28,25749 claims
Boehringer IngelheimJardiance$203$26,16226 claims
AstraZenecaFarxiga$673$25,07624 claims
AbbVieLinzess, Synthroid$1,057$14,52262 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →